Literature DB >> 427160

Methylation of DNAase-digestible DNA and of RNA in chromatin from rats treated with dimethylnitrosamine.

A I Galbraith, M Barker, R F Itzhaki.   

Abstract

After injecting rats with di[14C]methylnitrosamine we have prepared liver chromatin and have examined firstly, the methylation level of the DNAase I-degradable fraction of the DNA and secondly, the level of methylation and the stability of methylated sites in chromatin RNA. Our results show that the level of 7-methylguanine in the degradable DNA is about 1.3 times that of whole DNA; therefore in the 20% or so of the DNA which is undegradable by DNAase I, the level must be very low or zero. Experiments using chromatin from rats injected with unlabelled dimethylnitrosamine plus [3H]thymidine show that the specific activity is similar in the DNAase I degradable and undegradable fractions, suggesting that there is no preferential repair in the latter region. In chromatin RNA, the level of 7-methylguanine is higher than that of whole DNA and decreases fairly rapidly within 30 h after dimethylnitrosamine treatment. Our results indicate that this decrease is due to some type of excision or repair process rather than to normal turnover.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 427160     DOI: 10.1016/0005-2787(79)90142-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  Transient conformation changes in chromatin during excision repair of ultraviolet damage to DNA.

Authors:  W J Bodell; J E Cleaver
Journal:  Nucleic Acids Res       Date:  1981-01-10       Impact factor: 16.971

2.  The use of radioimmunoassay to study the formation and disappearance of O6-methylguanine in mouse liver satellite and main-band DNA following dimethylnitrosamine administration.

Authors:  S A Kyrtopoulos; P F Swann
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

3.  Interaction of chemical carcinogens with macromolecules.

Authors:  P J O'Connor
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.